What is Electromed's earnings per share (EPS)?

Electromed (ELMD) reported diluted earnings per share of $1.30 for fiscal year 2026. This represents a 52.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Electromed Financials

ELMD

FY2026 annual

Revenue $73.8M +15.3% YoY

Net Income $11.3M +49.9% YoY

EPS (Diluted) $1.30 +52.9% YoY

Free Cash Flow $8.4M -24.4% YoY

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Jun 30, 2026 Reported Aug 25, 2026 Currency USD FYE June

Electromed (ELMD) reported $73.8M in revenue for fiscal year 2026, up 15.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ELMD FY2026 2026-08-25

Electromed’s dominant mechanic is operating leverage: expanding sales are converting a stable gross margin into faster profit and cash growth.

From FY2024 to FY2026, net margin rose from 9.4% to 15.3% while gross margin moved only from 76.3% to 78.5%. That pattern points to operating leverage rather than a major product-margin reset, with more of each additional sales dollar reaching operating profit.

Cash conversion softened in FY2026: operating cash flow was $9.7M, below that year’s $11.3M net income. With receivables at $29.8M, the gap suggests growth is tying more cash into customer balances even while earnings remain profitable.

The balance sheet is funded conservatively: cash of $20.5M exceeded total liabilities of $12.3M. A $10.0M FY2025 buyback also shows that financing outflows, rather than operating weakness, can materially reduce cash.

Financial Health Signals

Financial Health Score 79/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Electromed's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Electromed has an operating margin of 18.8%, meaning the company retains $19 of operating profit per $100 of revenue. This strong profitability earns a score of 77/100, reflecting efficient cost management and pricing power. This is up from 15.1% the prior year.

Growth

Electromed's revenue surged 15.3% year-over-year to $73.8M, reflecting rapid business expansion. This strong growth earns a score of 77/100.

Leverage

Electromed carries a low D/E ratio of 0.23, meaning only $0.23 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 73/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.69, Electromed holds $4.69 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 89/100.

Cash Flow

Electromed converts 11.4% of revenue into free cash flow ($8.4M). This strong cash generation earns a score of 77/100.

Returns

Electromed earns a strong 20.9% return on equity (ROE), meaning it generates $21 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 82/100. This is up from 17.4% the prior year.

Altman Z-Score Safe

15.32

Electromed scores 15.32, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($247.6M) relative to total liabilities ($12.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/8

Electromed passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

0.86x

For every $1 of reported earnings, Electromed generates $0.86 in operating cash flow ($9.7M OCF vs $11.3M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$73.8M

YoY+15.3%

5Y CAGR+15.6%

10Y CAGR+12.4%

Electromed generated $73.8M in revenue in fiscal year 2026. This represents an increase of 15.3% from the prior year.

EBITDA

$14.8M

YoY+36.7%

5Y CAGR+31.6%

10Y CAGR+14.4%

Electromed's EBITDA was $14.8M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 36.7% from the prior year.

Net Income

$11.3M

YoY+49.9%

5Y CAGR+36.8%

10Y CAGR+17.7%

Electromed reported $11.3M in net income in fiscal year 2026. This represents an increase of 49.9% from the prior year.

EPS (Diluted)

$1.30

YoY+52.9%

5Y CAGR+36.9%

10Y CAGR+17.0%

Electromed earned $1.30 per diluted share (EPS) in fiscal year 2026. This represents an increase of 52.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$8.4M

YoY-24.4%

5Y CAGR+24.7%

10Y CAGR+17.8%

Electromed generated $8.4M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 24.4% from the prior year.

Cash & Debt

$20.4M

YoY+33.8%

5Y CAGR+11.5%

10Y CAGR+14.8%

Electromed held $20.4M in cash as of fiscal year 2026; long-term debt is not reported for that period.

Shares Outstanding

YoY+0.2%

5Y CAGR-0.5%

10Y CAGR+0.2%

Electromed had 8M shares outstanding in fiscal year 2026. This represents an increase of 0.2% from the prior year.

Dividends Per Share

Not reported for fiscal year 2026.

Margins & Returns

Gross Margin

78.5%

YoY+0.5pp

5Y CAGR+2.2pp

10Y CAGR+0.8pp

Electromed's gross margin was 78.5% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 0.5 percentage points from the prior year.

Operating Margin

18.8%

YoY+3.7pp

5Y CAGR+10.0pp

10Y CAGR+5.3pp

Electromed's operating margin was 18.8% in fiscal year 2026, reflecting core business profitability. This is up 3.7 percentage points from the prior year.

Net Margin

15.3%

YoY+3.5pp

5Y CAGR+8.7pp

10Y CAGR+5.7pp

Electromed's net profit margin was 15.3% in fiscal year 2026, showing the share of revenue converted to profit. This is up 3.5 percentage points from the prior year.

Return on Equity

20.9%

YoY+3.5pp

5Y CAGR+13.7pp

10Y CAGR+7.4pp

Electromed's ROE was 20.9% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 3.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.3M

YoY+31.9%

5Y CAGR-5.3%

10Y CAGR+13.2%

Electromed invested $1.3M in research and development in fiscal year 2026. This represents an increase of 31.9% from the prior year.

Share Buybacks

$3.9M

YoY-60.8%

5Y CAGR+28.4%

Electromed spent $3.9M on share buybacks in fiscal year 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 60.8% from the prior year.

Capital Expenditures

$1.3M

YoY+377.9%

5Y CAGR+34.3%

10Y CAGR+8.9%

Electromed invested $1.3M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents an increase of 377.9% from the prior year.

ELMD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ELMD quarterly income statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Revenue	$73.8M+15.3%	$64.0M+17.0%	$54.7M+13.8%	$48.1M+15.4%	$41.7M+16.5%	$35.8M+10.1%	$32.5M+3.7%	$31.3M+10.6%	$28.3M+9.5%	$25.9M+12.5%	$23.0M+18.5%	$19.4M+25.3%	$15.5M+2.5%	$15.1M-22.6%	$19.5M
Cost of Revenue	$15.8M+12.9%	$14.0M+8.0%	$13.0M+12.5%	$11.5M+13.0%	$10.2M+20.9%	$8.5M+16.2%	$7.3M-2.4%	$7.5M+14.0%	$6.5M+23.5%	$5.3M+3.5%	$5.1M-11.9%	$5.8M+19.7%	$4.9M+4.3%	$4.7M-13.5%	$5.4M
Gross Profit	$57.9M+16.0%	$50.0M+19.8%	$41.7M+14.3%	$36.5M+16.1%	$31.4M+15.2%	$27.3M+8.4%	$25.2M+5.7%	$23.8M+9.5%	$21.8M+5.9%	$20.6M+15.1%	$17.9M+31.4%	$13.6M+27.9%	$10.6M+1.8%	$10.4M-26.1%	$14.1M
R&D Expenses	$1.3M+31.9%	$996K+51.8%	$656K-28.4%	$916K-32.4%	$1.4M-21.3%	$1.7M+64.0%	$1.1M+80.0%	$583K+132.0%	$251K-57.9%	$597K+56.9%	$380K+20.5%	$316K-32.3%	$466K-22.8%	$603K-34.5%	$921K
SG&A Expenses	$42.7M+8.7%	$39.3M+14.0%	$34.5M+9.2%	$31.6M+16.5%	$27.1M+20.8%	$22.4M+12.5%	$19.9M-2.4%	$20.4M+8.6%	$18.8M+14.7%	$16.4M+14.0%	$14.4M+20.1%	$12.0M+9.8%	$10.9M-6.5%	$11.7M-7.5%	$12.6M
Operating Income	$13.9M+43.7%	$9.7M+46.8%	$6.6M+64.2%	$4.0M+34.9%	$3.0M-5.4%	$3.1M-38.6%	$5.1M+80.9%	$2.8M+4.3%	$2.7M-24.0%	$3.6M+14.8%	$3.1M+137.3%	$1.3M+276.9%	-$741K+59.5%	-$1.8M-401.4%	$606K
Interest Expense	N/A	N/A	$455K+483.3%	$78K+212.0%	$25K-7.4%	$27K-77.7%	$121K+33.4%	$91K+356.5%	$20K+139.8%	-$50K+25.4%	-$67K-177.9%	$86K+8.5%	$79K-32.4%	$117K-30.7%	$169K
Income Tax	$3.1M+11.4%	$2.7M+45.7%	$1.9M+105.0%	$920K+32.9%	$692K-14.0%	$805K-25.3%	$1.1M+14.7%	$940K+4.3%	$901K-30.2%	$1.3M+55.4%	$830K+528.8%	$132K-71.9%	$469K+176.3%	-$615K-345.0%	$251K
Net Income	$11.3M+49.9%	$7.5M+46.3%	$5.2M+62.7%	$3.2M+37.4%	$2.3M-2.4%	$2.4M-43.2%	$4.2M+110.1%	$2.0M+8.1%	$1.8M-17.9%	$2.2M+0.8%	$2.2M+102.5%	$1.1M+184.8%	-$1.3M+3.1%	-$1.3M-812.3%	$187K
EPS (Diluted)	$1.30+52.9%	$0.85+46.6%	$0.58+61.1%	$0.36+38.5%	$0.26-3.7%	$0.27-42.6%	$0.47+104.3%	$0.23+9.5%	$0.21-19.2%	$0.26-3.7%	$0.27+107.7%	$0.13+181.3%	-$0.16	N/A	$0.02

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Revenue	$19.4M+4.5%	$18.6M-1.7%	$18.9M+11.9%	$16.9M-2.9%	$17.4M+10.9%	$15.7M-3.5%	$16.3M+10.8%	$14.7M
Cost of Revenue	$4.1M+5.1%	$3.9M-3.6%	$4.1M+10.5%	$3.7M-2.1%	$3.8M+9.1%	$3.5M-4.8%	$3.6M+14.2%	$3.2M
Gross Profit	$15.3M+4.4%	$14.6M-1.2%	$14.8M+12.3%	$13.2M-3.1%	$13.6M+11.4%	$12.2M-3.2%	$12.6M+9.9%	$11.5M
R&D Expenses	$328K-9.1%	$361K-6.0%	$384K+59.3%	$241K-20.2%	$302K+9.0%	$277K+10.4%	$251K+51.2%	$166K
SG&A Expenses	$11.1M+5.8%	$10.5M-2.8%	$10.8M+5.1%	$10.3M0.0%	$10.3M+4.8%	$9.8M-0.2%	$9.8M+4.8%	$9.4M
Operating Income	$3.8M+1.6%	$3.8M+4.0%	$3.6M+35.6%	$2.7M-12.2%	$3.0M+42.1%	$2.1M-15.8%	$2.5M+31.2%	$1.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	$152K-22.1%	$195K
Income Tax	$560K-35.1%	$863K-10.8%	$968K+44.9%	$668K-31.2%	$971K+148.3%	$391K-46.1%	$726K+10.2%	$659K
Net Income	$3.4M+13.3%	$3.0M+8.8%	$2.8M+29.3%	$2.1M-3.1%	$2.2M+16.6%	$1.9M-3.9%	$2.0M+33.5%	$1.5M
EPS (Diluted)	$0.39+11.4%	$0.35+9.4%	$0.32+28.0%	$0.25-3.8%	$0.26+23.8%	$0.21-4.5%	$0.22+37.5%	$0.16

ELMD Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ELMD quarterly balance sheet

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Total Assets	$66.3M+23.2%	$53.8M+3.0%	$52.2M+14.0%	$45.8M+10.7%	$41.4M+11.5%	$37.1M+11.6%	$33.2M+13.1%	$29.4M+7.3%	$27.4M+18.8%	$23.1M+12.1%	$20.6M+18.2%	$17.4M+10.2%	$15.8M-10.0%	$17.6M-16.1%	$20.9M
Current Assets	$57.4M+27.3%	$45.1M+2.1%	$44.2M+16.9%	$37.8M+9.4%	$34.5M+8.9%	$31.7M+13.1%	$28.0M+14.2%	$24.5M+5.4%	$23.3M+26.0%	$18.5M+16.7%	$15.8M+25.7%	$12.6M+18.5%	$10.6M-14.5%	$12.4M-23.8%	$16.3M
Cash & Equivalents	$20.4M+33.8%	$15.3M-4.9%	$16.1M+118.1%	$7.4M-9.6%	$8.2M-31.4%	$11.9M+13.5%	$10.5M+34.2%	$7.8M+4.7%	$7.5M+33.8%	$5.6M+8.8%	$5.1M+42.4%	$3.6M+139.5%	$1.5M+198.4%	$504K-70.4%	$1.7M
Inventory	$3.7M+11.6%	$3.3M-11.1%	$3.7M-12.1%	$4.2M+32.8%	$3.2M+50.3%	$2.1M-31.5%	$3.1M+17.7%	$2.6M+5.4%	$2.5M-2.8%	$2.6M+3.2%	$2.5M+19.7%	$2.1M-7.3%	$2.2M+62.0%	$1.4M-42.3%	$2.4M
Accounts Receivable	$29.8M+20.9%	$24.7M+5.7%	$23.3M-3.3%	$24.1M+14.6%	$21.1M+23.6%	$17.0M+31.6%	$12.9M+1.4%	$12.8M+8.0%	$11.8M+18.7%	$9.9M+30.7%	$7.6M+16.8%	$6.5M+0.5%	$6.5M-28.0%	$9.0M-16.9%	$10.9M
Total Liabilities	$12.3M+16.0%	$10.6M+37.8%	$7.7M-5.5%	$8.1M+13.2%	$7.2M+53.2%	$4.7M+56.7%	$3.0M-18.3%	$3.7M-22.7%	$4.7M+18.8%	$4.0M-5.4%	$4.2M+21.2%	$3.5M+13.3%	$3.1M-15.4%	$3.6M-37.9%	$5.8M
Current Liabilities	$12.2M+16.8%	$10.5M+36.4%	$7.7M-4.7%	$8.1M+12.6%	$7.2M+54.1%	$4.6M+55.4%	$3.0M-18.2%	$3.7M-24.0%	$4.8M+65.9%	$2.9M-5.7%	$3.1M+34.8%	$2.3M+25.2%	$1.8M-17.0%	$2.2M-47.4%	$4.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.1M-4.3%	$1.1M-4.7%	$1.2M-3.9%	$1.3M-6.1%	$1.3M-4.1%	$1.4M
Total Equity	$54.0M+24.9%	$43.2M-3.0%	$44.5M+18.3%	$37.7M+10.2%	$34.2M+5.4%	$32.4M+7.2%	$30.3M+17.5%	$25.7M+14.0%	$22.6M+13.8%	$19.8M+21.2%	$16.4M+17.5%	$13.9M+9.5%	$12.7M-8.7%	$13.9M-7.6%	$15.1M
Retained Earnings	$28.6M+34.8%	$21.2M-10.5%	$23.7M+25.9%	$18.8M+19.1%	$15.8M+5.7%	$14.9M+9.0%	$13.7M+43.7%	$9.5M0.0%	$9.5M+92.1%	$5.0M+81.8%	$2.7M+429.9%	$515K+189.1%	-$578K-181.3%	$711K-65.2%	$2.0M

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Total Assets	$66.3M+11.4%	$59.5M+8.3%	$54.9M+2.4%	$53.6M-0.3%	$53.8M+2.6%	$52.5M+0.3%	$52.3M+6.9%	$48.9M
Current Assets	$57.4M+14.2%	$50.2M+10.2%	$45.6M+2.3%	$44.6M-1.2%	$45.1M+2.0%	$44.2M0.0%	$44.2M+7.8%	$41.0M
Cash & Equivalents	$20.4M+20.4%	$17.0M+23.2%	$13.8M-2.3%	$14.1M-7.7%	$15.3M+0.3%	$15.2M-6.1%	$16.2M+17.1%	$13.9M
Inventory	$3.7M+11.7%	$3.3M-4.7%	$3.5M-8.3%	$3.8M+14.3%	$3.3M+11.2%	$3.0M-3.7%	$3.1M-10.3%	$3.4M
Accounts Receivable	$29.8M+5.5%	$28.3M+7.6%	$26.3M+6.1%	$24.8M+0.4%	$24.7M+5.2%	$23.4M+2.9%	$22.8M+1.8%	$22.4M
Total Liabilities	$12.3M+19.2%	$10.3M+8.8%	$9.5M+6.8%	$8.9M-16.3%	$10.6M+24.5%	$8.5M-1.8%	$8.7M+16.7%	$7.4M
Current Liabilities	$12.2M+19.5%	$10.2M+9.1%	$9.4M+7.0%	$8.8M-16.3%	$10.5M+23.0%	$8.5M-1.8%	$8.7M+16.8%	$7.4M
Total Equity	$54.0M+9.8%	$49.2M+8.2%	$45.4M+1.6%	$44.7M+3.6%	$43.2M-1.7%	$43.9M+0.8%	$43.6M+5.1%	$41.5M
Retained Earnings	$28.6M+13.6%	$25.1M+12.8%	$22.3M-0.1%	$22.3M+5.3%	$21.2M-6.1%	$22.6M-0.1%	$22.6M+9.7%	$20.6M

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

ELMD Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

ELMD quarterly cash flow statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Operating Cash Flow	$9.7M-15.2%	$11.4M+25.7%	$9.1M+589.5%	$1.3M+291.7%	-$686K-122.3%	$3.1M-26.7%	$4.2M+62.0%	$2.6M+6.0%	$2.4M+105.0%	$1.2M-45.0%	$2.2M-22.1%	$2.8M+34.5%	$2.1M+10.2%	$1.9M+260.2%	-$1.2M
Capital Expenditures	$1.3M+377.9%	$262K-8.7%	$287K-82.6%	$1.6M+15.6%	$1.4M+396.5%	$287K-66.0%	$844K-36.6%	$1.3M+152.9%	$526K-15.0%	$619K+15.7%	$535K+2.2%	$523K-41.6%	$895K-11.9%	$1.0M+28.4%	$792K
Free Cash Flow	$8.4M-24.4%	$11.1M+26.8%	$8.8M+2736.6%	-$333K+84.2%	-$2.1M-175.7%	$2.8M-16.8%	$3.4M+166.2%	$1.3M-34.3%	$1.9M+234.8%	$572K-64.9%	$1.6M-27.7%	$2.3M+92.7%	$1.2M+36.3%	$860K+143.8%	-$2.0M
Investing Cash Flow	-$1.3M-324.8%	-$306K+22.5%	-$395K+77.0%	-$1.7M-12.5%	-$1.5M-240.4%	-$448K+54.1%	-$977K+29.5%	-$1.4M-142.5%	-$572K+16.8%	-$687K-18.6%	-$580K	N/A	N/A	N/A	-$849K
Financing Cash Flow	-$3.2M+73.0%	-$11.9M-33100.0%	$36K+109.5%	-$380K+75.1%	-$1.5M-25.1%	-$1.2M-122.4%	-$548K+35.6%	-$851K-7367.3%	$12K+121.8%	-$54K+13.9%	-$62K-1.8%	-$61K	N/A	N/A	-$369K
Share Buybacks	$3.9M-60.8%	$10.0M+3536.4%	$275K+79.7%	$153K-89.4%	$1.4M+28.8%	$1.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Operating Cash Flow	$3.0M-13.9%	$3.5M+14.9%	$3.0M+1690.5%	$169K-95.6%	$3.9M+86.1%	$2.1M-34.2%	$3.2M+36.5%	$2.3M
Capital Expenditures	$219K+49.0%	$147K-76.8%	$634K+151.6%	$252K+73.8%	$145K-5.2%	-$153K-34.3%	$233K+529.7%	$37K
Free Cash Flow	$2.8M-16.6%	$3.3M+39.2%	$2.4M+2981.9%	-$83K-102.2%	$3.7M+93.3%	$1.9M-34.2%	$2.9M+28.4%	$2.3M
Investing Cash Flow	-$223K-44.8%	-$154K+76.5%	-$656K-145.7%	-$267K-70.1%	-$157K-207.5%	$146K+161.6%	-$237K-308.6%	-$58K
Financing Cash Flow	$694K+642.2%	-$128K+95.2%	-$2.7M-150.2%	-$1.1M+70.5%	-$3.7M-13.5%	-$3.2M-492.6%	-$543K+87.8%	-$4.5M
Share Buybacks	$0-100.0%	$152K-94.5%	$2.8M+175.5%	$1.0M-72.7%	$3.7M+104.4%	$1.8M	$0-100.0%	$4.5M

Not reported in any period shown, so not listed: Dividends Paid.

ELMD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

ELMD quarterly financial ratios

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Gross Margin	78.5%+0.5pp	78.1%+1.8pp	76.3%+0.3pp	76.0%+0.5pp	75.5%-0.9pp	76.4%-1.3pp	77.6%+1.4pp	76.2%-0.7pp	76.9%-2.6pp	79.5%+1.8pp	77.8%+7.7pp	70.1%+1.4pp	68.7%-0.5pp	69.2%-3.3pp	72.5%
Operating Margin	18.8%+3.7pp	15.1%+3.1pp	12.0%+3.7pp	8.3%+1.2pp	7.1%-1.7pp	8.8%-7.0pp	15.8%+6.7pp	9.0%-0.5pp	9.6%-4.2pp	13.8%+0.3pp	13.5%+6.8pp	6.8%+11.5pp	-4.8%+7.3pp	-12.1%-15.2pp	3.1%
Net Margin	15.3%+3.5pp	11.8%+2.4pp	9.4%+2.8pp	6.6%+1.1pp	5.5%-1.1pp	6.6%-6.2pp	12.8%+6.5pp	6.3%-0.1pp	6.5%-2.2pp	8.6%-1.0pp	9.6%+4.0pp	5.6%+14.0pp	-8.3%+0.5pp	-8.8%-9.8pp	1.0%
Return on Equity	20.9%+3.5pp	17.4%+5.9pp	11.6%+3.1pp	8.4%+1.7pp	6.8%-0.5pp	7.3%-6.5pp	13.8%+6.1pp	7.7%-0.4pp	8.1%-3.1pp	11.2%-2.3pp	13.5%+5.7pp	7.8%+18.0pp	-10.1%-0.6pp	-9.5%-10.8pp	1.2%
Return on Assets	17.1%+3.0pp	14.0%+4.2pp	9.9%+2.9pp	6.9%+1.3pp	5.6%-0.8pp	6.4%-6.2pp	12.5%+5.8pp	6.7%+0.1pp	6.7%-3.0pp	9.7%-1.1pp	10.8%+4.5pp	6.3%+14.4pp	-8.2%-0.6pp	-7.6%-8.5pp	0.9%
Current Ratio	4.69+0.4x	4.31-1.4x	5.75+1.1x	4.69-0.1x	4.83-2.0x	6.83-2.6x	9.38+2.7x	6.72+1.9x	4.85-1.5x	6.38+1.2x	5.15-0.4x	5.52-0.3x	5.84+0.2x	5.66+1.8x	3.91
Debt-to-Equity	0.230.0x	0.25+0.1x	0.170.0x	0.220.0x	0.21+0.1x	0.140.0x	0.100.0x	0.14-0.1x	0.21+0.2x	0.060.0x	0.070.0x	0.090.0x	0.100.0x	0.100.0x	0.09
FCF Margin	11.4%-6.0pp	17.4%+1.3pp	16.1%+16.7pp	-0.7%+4.4pp	-5.1%-12.9pp	7.8%-2.5pp	10.3%+6.3pp	4.0%-2.7pp	6.8%+4.6pp	2.2%-4.9pp	7.1%-4.5pp	11.6%+4.1pp	7.6%+1.9pp	5.7%+15.8pp	-10.1%

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Gross Margin	78.7%-0.1pp	78.8%+0.4pp	78.4%+0.3pp	78.1%-0.2pp	78.3%+0.4pp	78.0%+0.3pp	77.7%-0.7pp	78.3%
Operating Margin	19.7%-0.6pp	20.3%+1.1pp	19.2%+3.4pp	15.8%-1.7pp	17.5%+3.8pp	13.6%-2.0pp	15.6%+2.4pp	13.2%
Net Margin	17.5%+1.3pp	16.2%+1.6pp	14.6%+2.0pp	12.7%0.0pp	12.7%+0.6pp	12.1%-0.1pp	12.1%+2.1pp	10.1%
Return on Equity	6.3%+0.2pp	6.1%0.0pp	6.1%+1.3pp	4.8%-0.3pp	5.1%+0.8pp	4.3%-0.2pp	4.5%+1.0pp	3.5%
Return on Assets	5.1%+0.1pp	5.1%0.0pp	5.0%+1.0pp	4.0%-0.1pp	4.1%+0.5pp	3.6%-0.2pp	3.8%+0.8pp	3.0%
Current Ratio	4.69-0.2x	4.91+0.1x	4.86-0.2x	5.09+0.8x	4.31-0.9x	5.19+0.1x	5.10-0.4x	5.53
Debt-to-Equity	0.230.0x	0.210.0x	0.210.0x	0.200.0x	0.25+0.1x	0.190.0x	0.200.0x	0.18
FCF Margin	14.3%-3.6pp	17.9%+5.3pp	12.7%+13.1pp	-0.5%-21.8pp	21.3%+9.1pp	12.3%-5.7pp	17.9%+2.5pp	15.5%

Similar Companies

Inogen Inc INGN

$147.6M

Neuronetics STIM

$228.6M

Cvrx, Inc. CVRX

$87.1M

BioSig Technologies Inc BSGM

$157.0M

Sight Sciences, Inc. SGHT

$461.1M

Where Electromed Ranks

Frequently Asked Questions

What is Electromed's annual revenue?

Electromed (ELMD) reported $73.8M in total revenue for fiscal year 2026. This represents a 15.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Electromed's revenue growing?

Electromed (ELMD) revenue grew by 15.3% year-over-year, from $64.0M to $73.8M in fiscal year 2026.

Is Electromed profitable?

Yes, Electromed (ELMD) reported a net income of $11.3M in fiscal year 2026, with a net profit margin of 15.3%.

What is Electromed's EBITDA?

Electromed (ELMD) had EBITDA of $14.8M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

What is Electromed's gross margin?

Electromed (ELMD) had a gross margin of 78.5% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Electromed's operating margin?

Electromed (ELMD) had an operating margin of 18.8% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Electromed's net profit margin?

Electromed (ELMD) had a net profit margin of 15.3% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is Electromed's return on equity (ROE)?

Electromed (ELMD) has a return on equity of 20.9% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Electromed's free cash flow?

Electromed (ELMD) generated $8.4M in free cash flow during fiscal year 2026. This represents a -24.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Electromed's operating cash flow?

Electromed (ELMD) generated $9.7M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Electromed's total assets?

Electromed (ELMD) had $66.3M in total assets as of fiscal year 2026, including both current and long-term assets.

What are Electromed's capital expenditures?

Electromed (ELMD) invested $1.3M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Electromed spend on research and development?

Electromed (ELMD) invested $1.3M in research and development during fiscal year 2026.

Does Electromed buy back shares?

Yes, Electromed (ELMD) spent $3.9M on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

How many shares does Electromed have outstanding?

Electromed (ELMD) had 8M shares outstanding as of fiscal year 2026.

What is Electromed's current ratio?

Electromed (ELMD) had a current ratio of 4.69 as of fiscal year 2026, which is generally considered healthy.

What is Electromed's debt-to-equity ratio?

Electromed (ELMD) had a debt-to-equity ratio of 0.23 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Electromed's return on assets (ROA)?

Electromed (ELMD) had a return on assets of 17.1% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Electromed's Altman Z-Score?

Electromed (ELMD) has an Altman Z-Score of 15.32, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Electromed's Piotroski F-Score?

Electromed (ELMD) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Electromed's earnings high quality?

Electromed (ELMD) has an earnings quality ratio of 0.86x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Electromed?

Electromed (ELMD) scores 79 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.